Certolizumab pegol, in combination with methotrexate (MTX), is indicated for:
Certolizumab pegol has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.
For this indication, competent medicine agencies globally authorize below treatments:
200 - 400 mg
From 200 To 400 mg once every 14 day(s)
The recommended starting dose of certolizumab for adult patients is 400 mg (given as 2 subcutaneous injections of 200 mg each) at weeks 0, 2 and 4.
After the starting dose, the recommended maintenance dose of certolizumab for adult patients with rheumatoid arthritis is 200 mg every 2 weeks. Once clinical response is confirmed, an alternative maintenance dosing of 400 mg every 4 weeks can be considered. MTX should be continued during treatment with certolizumab where appropriate.
Patients who miss a dose should be advised to inject the next dose of certolizumab as soon as they remember and then continue injecting subsequent doses as instructed.
Suitable sites for injection would include the thigh or abdomen.